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Methylxanthines	 are	 the	most	 widely	 consumed	 drugs	 in	 the	 world	 and	 evidence	 of	 their	 health	27	
benefits	has	been	growing	in	recent	years.	Primary	Amine	Oxidase	(PrAO)	has	been	recognised	as	a	28	
therapeutic	 target	 for	 amelioration	 of	 inflammatory,	 vascular	 and	 neurodegenerative	 diseases.	29	
Previous	work	 in	our	 laboratories	 showed	 that	 caffeine	 inhibited	Bovine	PrAO	with	a	Ki	of	1.0mM	30	
using	benzylamine	as	substrate.		31	
This	 study	 aimed	 to	 extend	 our	 previous	 work	 and	 explore	 the	 possibility	 that	 related	32	





















range	 from	 lowering	 of	 inflammation	 to	 the	 prevention	 of	 neurodegenerative	 disease	 (Chrysant	52	
(2017),	Kolahdouzan	M	and	Hamadeh	(2017).	The	effects	of	methylxanthines	are	primarily	thought	53	
to	be	due	to	their	binding	to	adenosine	receptors	(Monteiro	et	al.,	2016,	Salomone	et	al.,	2017).		54	
Primary	 Amine	 Oxidase	 (PrAO)	 is	 a	 copper-containing	 transmembrane	 glycoprotein	 that	 catalyses	55	
the	following	reaction:	56	
RCH2NH2		+		H2O		+		O2			---˃			RCHO		+		NH3		+		H2O2.	57	
It	 contains	 a	 cytoplasmic	 domain,	 a	 transmembrane	 segment	 and	 an	 extracellular	 domain.	 In	 the	58	
vascular	endothelium	the	extracellular	domain	may	be	cleaved	off	to	give	rise	to	a	circulating	form	59	
found	in	plasma.	 In	some	tissues,	the	membrane	form	acts	as	a	Vascular	Adhesion	Protein	(VAP-1)	60	
which	 is	 involved	 in	 the	 migration	 of	 leukocytes	 through	 the	 vascular	 endothelium	 at	 sites	 of	61	
inflammation	(Pannecoeck	et	al.,	2015).	This	extravasion	process	requires	the	amine	oxidase	activity	62	
catalyzed	 by	 PrAO	 to	 be	 intact	 (Noonan	 et	 al.,	 2013).	 	 Both	 the	 circulating	 plasma	 form	 and	 the	63	
membrane	associated	PrAO	are	active	 in	amine	oxidation	and	their	endogenous	substrates	 include	64	
methylamine	and	aminoacetone	 (see	 Lyles,	 1996).	 These	 substrates	are	 converted	by	PrAO	 to	 the	65	
toxic	aldehydes	formaldehyde	and	methylglyoxal	respectively:	such	aldehydes	can	crosslink	proteins	66	
in	vivo	giving	rise	to	vascular	damage	(e.g.	Unzeta	et	al.,	2007).		Finally,	it	has	been	shown	that	H2O2	67	




has	made	 it	an	 important	therapeutic	target	(O’Sullivan	et	al.,	2004).	 Inhibitors	of	PrAO	have	been	72	
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reported	 and	 its	 inhibition	 is	 known	 to	 have	 anti-inflammatory	 effects	 and	 to	 positively	 influence	73	




Olivieri	 and	 Tipton,	 2011).	 	 A	 subsequent	 study	 (Che	 et	 al.,	 2012)	 showed	 that	 caffeine	78	
administration	 to	 rats	 inhibited	 PrAO	 activity	 in	 serum,	 brain	 and	 adipose	 tissue	 and	 raised	 the	79	
possibility	 that	 caffeine	 could	 be	 used	 in	 treating	 PrAO-associated	 disease.	 	 Trials	 assessing	 the	80	
impact	of	caffeine	on	PrAO	activity	in	human	subjects	have	been	considered	but	have	not	yet	been	81	
initiated	 (see	 https://clinicaltrials.gov/ct2/show/NCT02098785).	 The	 ability	 of	 dietary	 caffeine	 to	82	
inhibit	PrAO	 in	vivo	 is	highly	significant	and	points	to	the	possibility	that	 ingested	food	compounds	83	
might	influence	PrAO	in	humans	in	a	similar	manner	to	that	seen	in	rat	tissues	(Che	et	al.,	2012).		84	
Recently,	 a	 study	 in	 human	 adipose	 tissue	 found	 that	 phenolic	 compounds	 in	 food	 blocked	 the	85	
downstream	effects	of	H2O2	produced	by	PrAO	albeit	without	directly	inhibiting	PrAO	activity	(Les	et	86	
al.,	2016).	 It	 is	plausible	 that	 food	components	could	be	 responsible	 for	modulating	 the	activity	of	87	
PrAO	and	that	such	modulation	might	be	a	significant	health	benefit	for	people	on	a	diet	enriched	in	88	
PrAO	inhibiting	components.		89	
While	our	previous	 findings	 showed	caffeine	 to	be	a	PrAO	 inhibitor	 there	 is	no	 information	 in	 the	90	
literature	 concerning	 PrAO	 inhibition	 by	 other	 methylxanthines.	 It	 was,	 therefore,	 of	 interest	 to	91	
examine	whether	 caffeine-related	 compounds	might	 contribute	 to	modulation	of	 PrAO	activity.	 In	92	
this	 study	 we	 examined	 theobromine,	 paraxanthine,	 theophylline,	 7-methylxanthine	 and	 their	93	
derivatives	 as	modulators	 of	 bovine	 PrAO	 activity.	 Caffeine	 is	 found	 in	 the	 diet	mainly	 in	 tea	 and	94	
coffee	 and	 as	 a	 component	 of	 energy	 drinks	 (Olivieri	 et	 al.,	 2011,	 Olivieri	 A	 and	 Tipton	 2011).	95	
Theobromine	 and	 theophylline	 are	 ingested	 in	 tea	 and	 chocolate	 respectively	 (Monteiro	 et	 al.,	96	
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the	method	 of	 Holt	 and	 Palcic	 (2006),	 in	 the	 presence	 of	 5.0	mM	benzylamine.	 The	 chromogenic	103	




using	 a	 SpectraMax	340PC	plate	 reader	 (Molecular	Devices,	 Inc.	 Sunnyvale,	 CA	94089-1136,	USA).	108	
Control	assays	 for	 the	coupling	system,	 in	 the	presence	of	10	µM	H2O2,	1	mU/ml	HRP	but	without	109	
PrAO,	 showed	 that	 none	 of	 the	 compounds	 affected	 the	 chromogenic	 detection	 system.	 Each	110	
compound	was	assayed	in	triplicate,	at	a	final	concentration	of	0.5	or	1.0	mM.		111	
Data	analysis	and	curve	fitting:	Data	for	each	methylxanthine	tested	as	an	inhibitor	was	obtained	in	112	
three	 separate	 experiment	 each	 conducted	 in	 triplicate.	 Data	 are	 reported	 as	mean	 +/-	 standard	113	


















inhibitors.	 Figure	 3	 shows	 that	 neither	 xanthine,	 its	 metabolites	 hypoxanthine	 and	 uric	 acid,	 or	130	
imidazole	had	a	significant	inhibitory	effect	on	PrAO	activity	at	the	concentrations	used.			131	
……FIGURE	3	HERE…….	132	
Since	 theobromine	 was	 the	 only	 compound	 showing	 activity	 comparable	 to	 that	 of	 caffeine	 its	133	
interaction	with	PrAO	it	was	examined	in	greater	detail.		The	pattern	of	inhibition	with	theobromine	134	








































metabolites	 of	 caffeine.	 Assessing	 the	 combined	 effect	 of	 such	 compounds	will	 require	 animal	 or	170	
preferably	human	trials.	It	is	also	worth	noting	that,	in	recent	years,	theobromine	supplements	have	171	
become	widely	available	online	as	powders,	 capsules	and	pills	 for	 treatment	of	weight	 loss,	blood	172	
pressure	and	cancer,	among	other	conditions.			173	
Structure	 activity	 relationships:	 Of	 particular	 importance	 was	 the	 observation	 that	 none	 of	 the	174	
methylxanthines	besides	caffeine	and	theobromine	showed	significant	inhibition.	This	allowed	us	to	175	
identify	 structural	 features	 necessary	 for	 inhibition.	 Thus,	 7-methylxanthine,	 a	 caffeine	 derivative	176	
lacking	 a	 methyl	 group	 at	 position	 3,	 shows	 little	 inhibition.	 Similarly,	 theophylline,	 lacking	 the	177	









interpreted	 as	 the	 binding	 of	 inhibitor	 to	 a	 site	 other	 than	 the	 active	 site	 (Figure	 5).	 Thus,	 the	187	
inhibitor	may	bind	to	both	free	enzyme	and	the	enzyme	substrate	complex.	However,	the	ping-pong	188	









An	 imidazoline	binding	 site	on	PrAO	has	been	 indicated	 in	previous	 studies	 (Holt	et	al.,	 2008)	and	196	
two	imidazole	binding	sites	have	been	identified	on	a	crystal	structure	of	human	PrAO	(Elovaara	et	197	
al.,	2011).	The	crystal	structure	showed	imidazole	bound	to	the	topaquinone	(TPQ)	cofactor	of	both	198	
the	 oxidised	 and	 reduced	 forms	 of	 PrAO.	 	 It	 is	 possible	 that	 one	 of	 these	 sites	 might	 bind	 the	199	
methylxanthines	 of	 this	 study.	 Theobromine	 and	 caffeine	 presumably	 interact	 via	 hydrogen	 bond	200	
formation	with	 residues	 of	 PrAO.	 Comparison	with	 the	 other	 structures	 considered	 herein	 shows	201	
that	 inhibition	 is	 quite	 specific	 requiring	 the	 particular	 pattern	 of	 N-methylation	 only	 found	 in	202	
caffeine	and	theobromine.		203	
The	well-known	positive	effects	of	caffeine	and	theobromine	on	vascular	health,	 inflammation	and	204	
neurodegenerative	 disease	 have	 been	 variously	 attributed	 to	 binding	 at	 adenosine	 receptors,	205	
phosphodiesterase	 inhibition,	 binding	 to	 GABA	 receptors	 or	 calcium	 regulation	 (Monteiro	 et	 al.,	206	
2016).	 Inhibition	 of	 PrAO	 has	 not	 been	 considered	 as	 significant	 in	 this	 process;	 however,	 the	207	
benefits	ascribed	to	methylxanthines	mirror	those	associated	with	PrAO	inhibition.		It	is	conceivable	208	
that	 modulation	 of	 PrAO	 activity	 by	 ingested	 methylxanthines	 and	 their	 metabolites	 might	209	
contribute	 to	 lowering	 PrAO	 activity	 in	 vivo.	 This	 in	 turn	 might	 account	 for	 the	 known	 dietary	210	
advantage	associated	with	consumption	of	compounds	in	this	class.		211	
A	great	deal	of	effort	has	been	directed	towards	the	development	of	specific	inhibitors	of	PrAO	but	212	




site	 identified	 here	 might	 offer	 an	 attractive	 target	 for	 PrAO	 inhibitor	 design	 since	 it	 can	 inhibit	215	
activity	 without	 affecting	 substrate	 affinity:	 a	 noncompetitive	 inhibitor,	 unlike	 a	 competitive	216	
inhibitor,	 will	 not	 be	 affected	 by	 fluctuations	 in	 the	 physiological	 concentration	 of	 substrates	217	
available	to	PrAO.			218	
It	 is	 worth	 noting	 that	 caffeine	 derivatives	 have	 been	 explored	 previously	 in	 the	 treatment	 of	219	
neurodegenerative	 disease	 (Petzer	 and	 Petzer	 2015,	 Pohanka	 2015).	 For	 example,	 substitution	 at	220	
position	 8	 in	 caffeine	 to	 give	 8-chlorostyrylcaffeine,	 produces	 a	 powerful	 reversible	 inhibitor	 of	221	
monoamine	oxidase	B	(Binda	et	al,	2006).	Likewise,	substitutions	on	the	nitrogen	atom	at	position	1	222	
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Figure	 1:	 Structures	 of	 the	 methylxanthines	 considered	 in	 this	 study.	 These	 naturally-occurring	 compounds	 are	 all	 N-330	
methylated	derivatives	of	xanthine.		331	




Figure	 3.	 	 Effect	 of	 xanthine	 and	 related	 compounds	 on	 PrAO	 activity.	 	 Assays	 were	 carried	 out	 at	 370C	 and	 pH	 7.4	 as	336	
described	in	materials	and	methods.	The	control	was	a	standard	assay	of	PrAO	in	the	presence	of	5.0	mM	Benzylamine.		All	337	
data	are	 the	mean±SEM	of	 three	 separate	determinations.	 Asterisks	 denote	a	 significant	 difference	between	 treatments	338	
and	the	control	(*P	≤	0.05;	**P	≤	0.01;	***P	≤	0.001)	using	Dunnett’s	test.	339	
Figure	4.	 (a)	Pattern	of	 inhibition	of	PrAO	by	 theobromine.	Assays	were	 carried	out	as	 indicated	 in	 the	methods	 section.	340	
Benzylamine	concentration	was	varied	between	1.0	and	5.0mM	at	various	concentrations	of	caffeine:	0,	100,	200,	300,	400,	341	
500,	600µM.	The	Lineweaver	Burk	plots	are	shown	for	illustrative	purposes	only:	each	data	set	was	fitted	to	a	rectangular	342	
hyperbola	and	Kmapp	and	Vmax	estimated	by	non-linear	 regression	with	 the	aid	of	Graph	Pad	Prism	5.0.	 (b)	A	 replot	of	343	
slopes	(Kmapp/Vmax)	for	each	line	in	Fig	4a	versus	theobromine	concentration	was	used	to	estimate	Ki.	A	Ki	of	276±	44	µM	344	
mean	±	SEM	(n=3)	was	estimated.		345	
Figure	 5.	 	 Noncompetitive	 inhibition	mechanism.	Where	 E	 represents	 enzyme,	 S,	 the	 substrate,	 P	 the	 product	 and	 I	 the	346	



























































































































































































































































































Ki Plot of Inhibition of PrAO with Theobromine













 Figure 5 
K 
Ki Ki 
k 
